Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7803103 | 0.86 | ADRA1A (0.46) | ADRA1ATAAR1P2RX3ABCB1AOC3 | |
| SCHEMBL7803101 | 0.85 | CALM1 (0.44) | MTNR1AMTNR1BADRA1ATAAR1P2RX3 | |
| SCHEMBL7795285 | 0.85 | ENPP1 (0.45) | ADRA1ATAAR1P2RX3ABCB1AOC3 | |
| SCHEMBL8439119 | 0.85 | MAP4K4 (0.54) | ADRA1ATAAR1P2RX3AOC3DHFR | |
| SCHEMBL7796255 | 0.81 | ADRA1A (0.41) | ADRA1ATAAR1P2RX3ABCB1AOC3 | |
| SCHEMBL12844505 | 0.81 | MTNR1B (0.60) | MTNR1AMTNR1BADRA1AEGFRLCK | |
| SCHEMBL7796168 | 0.78 | MTNR1B (0.43) | MTNR1AMTNR1BP2RX3KMT2A | |
| SCHEMBL7796198 | 0.78 | MTNR1A (0.46) | MTNR1AMTNR1BADRA1ATAAR1P2RX3 | |
| SCHEMBL7804802 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BDHFREGFRLCK | |
| SCHEMBL7804833 | 0.76 | IP6K1 (0.57) | ADRA1ATAAR1P2RX3DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242686-A1 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | KRIWET KATRIN | 2008-10-02 | — | — | US | claimed |
| EP-0815087-B1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | claimed |
| US-5990116-A | USE IN PREVENTION OR TREATMENT OF INFLAMMATORY AND PROLIFERATIVE SKIN DISEASES AND CANCER; COMPOUNDS SUCH AS 6-(2-(2,5-DIMETHOXYPHENYL)ETHYL)-4-ETHYL-QUINAZOLINE | NOVARTIS AG (CH) | 1999-11-23 | — | — | US | claimed |
| EP-0815087-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | Novartis AG (CH) | 1998-01-07 | — | — | EP | claimed |
| WO-1996028430-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 1996-09-19 | — | — | WO | claimed |
| WO-2016167361-A1 | METHOD FOR PRODUCING ORGANIC COMPOUND SUBSTANTIALLY FREE OF Pd, AND NOVEL METHOD FOR REMOVING Pd FROM ORGANIC COMPOUND USING HYDROGEN GAS | アステラス製薬株式会社 | 2016-10-20 | — | — | WO | disclosed |
| US-20080242686-A1 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | KRIWET KATRIN | 2008-10-02 | — | — | US | disclosed |
| EP-1675621-B1 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060205746-A1 | Pharmaceutical compositions | KRIWET KATRIN | 2006-09-14 | — | — | US | disclosed |
| EP-1675621-A2 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | Novartis AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005016322-A2 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| EP-0815087-B1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-5990116-A | USE IN PREVENTION OR TREATMENT OF INFLAMMATORY AND PROLIFERATIVE SKIN DISEASES AND CANCER; COMPOUNDS SUCH AS 6-(2-(2,5-DIMETHOXYPHENYL)ETHYL)-4-ETHYL-QUINAZOLINE | NOVARTIS AG (CH) | 1999-11-23 | — | — | US | disclosed |
| EP-0815087-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028430-A1 | TRISUBSTITUTED PHENYL DERIVATIVES | NOVARTIS AG (CH) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205746-A1 | Pharmaceutical compositions | LRAT, ELOC, MLEC | MTNR1A 3076/4885MTNR1B 3450/4885ADRA1A 512/4885 |
| US-20080242686-A1 | PHARMACEUTICAL COMPOSITIONS OF LAVENDUSTIN | LYN, ELOC, TYR | MTNR1A 2203/4885MTNR1B 2570/4885ADRA1A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.